Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- BioAge Labs, Inc.BioAge Labs to Present at Upcoming Investor ConferencesBioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
- Innoviva, Inc.Innoviva to Participate in Upcoming Investor ConferencesBURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
- CG Oncology Inc.CG Oncology to Present at Upcoming Investor Conferences in SeptemberCG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
- North HighlandNorth Highland Names Chris Kido Global Head of Life SciencesATLANTA, September 02, 2026--North Highland, the leading change and transformation consultancy, today announced that Chris Kido has joined the Firm as global head of Life Sciences. Kido brings more than 25 years of experience leading business and technology strategy and transformation initiatives across pharma, biotech, and medical devices.
- PharmEquip Highlights Compact Thermal Solutions for Pharmaceutical ManufacturersPharmEquip is drawing attention to its range of compact heat transfer solutions for pharmaceutical and biotechnology manufacturers.
- Norroy Bioscience Co., Ltd.Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPCNORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a...
- Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical OfficerDr. Røpcke joins Resalis with extensive experience in clinical drug development as well as expertise in obesity and cardiometabolic therapy areas
- Nicox annonce l’extension de son horizon de trésorerie1 Estimation non auditée préparée par la Direction sur la base des informations disponibles à la date du présent communiqué de presse. La prochaine publication financière de la Société portera sur les comptes du premier semestre 2026 et interviendra en octobre 2026. 2 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA).
- IBA joins PFAROS European initiative to advance PFAS destruction for healthcare and pharmaceutical applicationsLouvain-la-Neuve, Belgium, 2 September 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research and innovation initiative launched to address environmental emissions and exposure concerns related to per- and polyfluoroalkyl substances (PFAS) in the pharmaceutical and medical sectors. As part of the project, IBA will co-lead the work on end-of-life and waste-management technologies, bringing its electron beam and Rhodotron® expertise to the assessment of PFAS destruction solutions.
- Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceMARSEILLE, France, September 02, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:
- מועד אחרון לתביעה ייצוגית נגד CAPR: רוזן, המייצג משקיעים וזוכה להערכה רבה, קורא למשקיעי חברת Capricor Therapeutics, Inc שספגו הפסדים העולים על 100,000 דולר לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה ייצוגית בניירות הערך – CAPRניו יורק, Sept. 02, 2026 -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Capricor Therapeutics, Inc. (נאסד"ק: CAPR), בין התאריכים 17 בדצמבר 2025 עד 26 ביולי 2026, שני התאריכים כוללים ("תקופת התביעה הייצוגית"), את המועד האחרון החשוב של 28 בספטמבר 2026 להגשת תביעה ייצוגית בניירות ערך.
- Ono Pharmaceutical Co., Ltd.Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesOSAKA, Japan & CAMBRIDGE, Mass., September 02, 2026--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; "Aitia").